Indole derivatives
Novel indole derivatives of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 is fluorine, or chlorine, and R 2 is hydrogen, or fluorine, which are SGLT inhibitors and are useful for treatment or prevention of diabetes and related conditions.
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein R 1 is fluorine, or chlorine, and R 2 is hydrogen, or fluorine.
2. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is fluorine and R 2 is hydrogen, or R 1 is chlorine and R 2 is hydrogen, or R 1 and R 2 are both fluorine.
3. The compound, or a pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is hydrogen.
4. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
4-chloro-3-(4-cyclopropylphenylmethyl)-1-(β-D-glucopyranosyl)indole,
3-(4-cyclopropylphenylmethyl)-4-fluoro-1-(β3-D-glucopyranosyl)indole,
4-chloro-3-(4-cyclopropylphenylmethyl)-6-fluoro-1-(β-D-glucopyranosyl)indole, and
3-(4-cyclopropylphenylmethyl)-4,6-difluoro-1-(β-D-glucopyranosyl)indole;
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof as set forth in claim 1 and a pharmaceutically acceptable carrier or diluent.
6. The pharmaceutical composition according to claim 5 , which further comprises another antidiabetic agent.
7. A compound, or a pharmaceutically acceptable salt thereof as set forth in claim 1 for use as an active therapeutic substance.
8. A method for treatment or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension, which comprises
administering to a mammal in need of treatment a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof as set forth in claim 1 .
9. A method for treatment of type 1 or type 2 diabetes mellitus, which comprises
administering to a mammal in need of treatment a therapeutically effective amount of the compound, or a pharmaceutically acceptable salt thereof as set forth in claim 1 alone, or in combination with another antidiabetic agent, an agent for treating diabetic complications, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent.
10. A process for preparing a compound of formula:
wherein R 1 is fluorine, or chlorine, and R 2 is hydrogen, or fluorine, or a pharmaceutically acceptable salt thereof, which comprises deprotecting a compound of formula (II)
wherein R 3 is a protecting group for hydroxyl group and the other symbols are the same as defined above, followed by converting the resulting compound into a pharmaceutically acceptable salt thereof, if desired.
11. A compound of formula (II)
wherein R 1 is fluorine or chlorine, R 2 is hydrogen or fluorine, and R 3 is a protecting group for a hydroxy group, or a pharmaceutically acceptable salt thereof.
12. A compound represented by the formula:
or a pharmaceutically acceptable salt thereof.